Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells

Author(s): Junben Wu , Muhammad Shahbaz , Shujing Wang , Bengang Gong , Benjia Liang , Ruliang Fang , Bo Qiu , Min Jiang , Yang Li , Jun Niu .

Journal Name: Current Signal Transduction Therapy

Volume 9 , Issue 2 , 2014

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objectives: As a selective matrix metalloproteinase inhibitor, MMI-166 specifically inhibits MMP-2 and MMP-9 activity and represses tumor invasion and metastasis. Previous studies show that MMI-166 has an anti-metastatic role in a variety of tumors. However, it still remains unclear about the exact effect of MMI-166 on human pancreatic cancer.

Methods: In this study, we showed firstly MMI-166 induced proliferation inhibition and apoptosis of SW1990 human pancreatic cancer cells in both dose- and time-dependent manners in vitro. We successfully established a human pancreatic cancer xenograft model in nude mice and verified the inhibition effect of MMI-166 on MMP-2 and MMP-9.

Results: More importantly, by using this model, we further demonstrated MMI-166 suppressed growth of SW1990 pancreatic cells xenograft in vivo by inducing cells apoptosis. In addition, we examined the expression of a series of apoptosis-related proteins and found MMI-166 inhibited the expression of c-Myc.

Conclusion: Our work demonstrates that MMI-166 may be of therapeutic value in the treatment of pancreatic cancer.

Keywords: Animal experimentation, apoptosis, cell proliferation, MMI-166, pancreatic neoplasms.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 2
Year: 2014
Page: [93 - 100]
Pages: 8
DOI: 10.2174/1574362409666141201202706
Price: $58

Article Metrics

PDF: 11